Table 4.
Association of the metabolic syndrome with endometrial cancer stratified by potential effect modifiers
| Cases/non-cases N |
HRa | 95% CI | P for heterogeneity | |
|---|---|---|---|---|
| Age (years) | ||||
| < 65 | 92/5,929 | 2.55 | 1.66–3.92 | 0.31 |
| ≥ 65 | 84/6,956 | 1.92 | 1.24–2.98 | |
| Smoking | ||||
| Never smoker | 101/6,663 | 1.73 | 1.16–2.59 | 0.05 |
| Ever smoker | 73/6,095 | 3.45 | 1.10–5.69 | |
| Missing | 2/127 | |||
| Hormone therapy use | ||||
| Never | 124/9,378 | 2.38 | 1.62–3.49 | 0.21 |
| Ever | 52/3,507 | 1.83 | 1.03–3.25 | |
| Hormone therapy use (excluding women from the HT intervention) | ||||
| Never | 96/6,188 | 2.61 | 1.71–3.99 | 0.17 |
| Ever | 38/2,469 | 1.72 | 0.88–3.35 | |
| BMI (kg/m2) | ||||
| 18.5–< 25.0 | 25/3,386 | 1.83 | 0.61–5.46 | 0.20 |
| 25.0–< 30.0 | 32/4,552 | 1.31 | 0.62–2.76 | |
| ≥ 30.0 | 116/4,859 | 1.57 | 1.04–2.36 | |
| Missing | 3/162 |
HT hormone therapy, BMI body mass index
a
With the exception of the stratifying variable, models were adjusted for age, pack-years of smoking, alcohol intake, physical activity, hormone therapy use, oral contraceptive use, menopausal status, education, ethnicity, allocation to the observational study or intervention/placebo/control arm of each clinical trial